Trade Ideas July 7, 2026 02:57 PM

Ares Capital: Market Is Discounting The Wrong Risks - Upgrade to Buy

High yield, discount to book, and an improving technical backdrop make ARCC an asymmetric income trade over the next 45 trading days

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
ARCC

Ares Capital (ARCC) yields ~10.3% and trades below book value with a $13.3B market cap. Recent headline risk around private credit has pressured the stock despite manageable portfolio metrics and improving technicals. We upgrade to Buy and recommend initiating a long at $18.50 with a $23.00 target and a $17.25 stop - mid-term (45 trading days) trade with an eye to longer-term upside if fundamentals normalize.

Ares Capital: Market Is Discounting The Wrong Risks - Upgrade to Buy
ARCC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • ARCC yields ~10.34% with a $0.48 quarterly dividend and trades below book (P/B ~0.95).
  • Market cap ~ $13.3B; shares outstanding ~718M; liquidity is adequate for tactical entry.
  • Recent quarter showed core EPS ~ $0.47 vs $0.48 dividend, but management cites realized gains and coverage over time.
  • Technicals neutral-to-positive: 10-day SMA <$18.53, RSI ~49.9, MACD shows bullish momentum - supportive for a mid-term trade.

Hook & thesis

Ares Capital (ARCC) is a classic income story that the market is mispricing. At $18.53 the stock yields about 10.3% and trades below book (P/B ~0.95) despite a long track record of dividend payments, a sizable loan book, and management messaging that core earnings and realized gains support the payout over time. Recent headlines about private credit liquidity have punished the group, but Ares is a listed BDC with daily liquidity and a much different risk profile than closed private funds that capped redemptions on 06/28/2026.

We think that noise has left a margin of safety for the patient income buyer. I am upgrading ARCC to Buy and proposing a tactical swing trade: enter at $18.50, stop at $17.25, target $23.00. Time the base case to mid term (45 trading days) while monitoring credit metrics and dividend coverage for a potential position hold out to 180 trading days if the story re-rates.

What the company does and why the market should care

Ares Capital is a publicly traded business development company that provides debt and equity financing to U.S. and Canadian companies, typically in the $10m - $250m EBITDA range. The firm underwrites mezzanine, buyout, acquisition, recapitalizations and growth financings and often takes a board seat as the lead investor. For income investors, the appeal is straightforward: high-yielding lending to middle-market borrowers with the earnings passed through as dividends.

Key market-relevant facts: the stock yields ~10.34% with a $0.48 quarterly dividend, market cap of roughly $13.3 billion, PE ~11.4 and P/B just under 1.00. Those numbers signal the market expects either rising credit losses or prolonged pressure on core earnings; we think the present market price overstates those risks relative to the company’s current portfolio performance and coverage dynamics.

Supporting evidence - numbers that matter

  • Dividend and yield: Quarterly dividend is $0.48; the headline dividend yield sits around 10.34%, which is what drives buy-and-hold interest from income investors.
  • Valuation: Market cap ~$13.3B and P/B ~0.95 - ARCC trades below book value, implying either depressed NAV or a market discount for perceived credit stress.
  • Recent operating context: The firm reported a quarterly core earnings miss (core EPS of about $0.47 in the most recent quarter vs the $0.48 payout), but management says overall earnings including realized gains provide coverage and the loan portfolio remains diversified.
  • Liquidity & size: Shares outstanding ~718.0M and two-week average volume ~5.5M, which means the position is liquid enough for most retail and institutional investors to enter and exit without exceptional friction.
  • Technicals: Short-term indicators are constructive enough for a tactical trade - 10-day SMA at $18.344 and 20-day EMA near $18.50 sit below or near the current price ($18.53). RSI ~49.9 is neutral and MACD shows bullish momentum, suggesting limited immediate downside from a technical perspective.

Valuation framing

ARCC’s P/B below 1.0 is the most telling signal: the market is effectively valuing the company at or below book value. For BDCs, NAV is the primary valuation anchor because their balance sheets are loans and securities whose mark-to-market or fair-value moves drive shareholder value. Trading below book typically indicates investor anxiety around credit quality or dividend sustainability; it does not automatically mean the underlying assets are impaired.

Compare the current price to the 52-week range: the stock has traded as high as $23.42 in the last year and as low as $17.40. A move to our $23.00 target would still sit a touch below the 52-week high, implying a re-rating toward historical levels rather than an aggressive multiple expansion. Given the company’s earnings power (consensus-like commentary references $2.02 core EPS on an annualized basis vs a $1.92 annual dividend in commentary) and the yield premium, a reversion toward book and prior cycle multiples is a reasonable base case if credit trends remain benign.

Catalysts (what will drive the re-rating)

  • Reassuring quarterly results and dividend coverage metrics - if core earnings and realized gains show coverage above the distribution, investors will rotate back into the stock.
  • Stabilization in private credit headlines - the market often overshoots on liquidity fears (see 06/28/2026 reporting that private funds limited redemptions), which should help ARCC as the reality of daily liquidity and portfolio transparency sinks in.
  • Improving credit spreads or higher net interest margin as the macro environment normalizes - upward pressure on loan yields can lift earnings faster than the market expects.
  • Share buybacks or capital redeployment announcements - repurchases at or below NAV are straightforward accretive actions for book value and per-share metrics.

Trade plan and execution

Actionable trade (upgrade to Buy):

Entry Target Stop Horizon
$18.50 $23.00 $17.25 Mid term (45 trading days)

Rationale: enter at $18.50, near current price, to capture both the dividend yield and upside to a restoration of P/B. Stop at $17.25 to limit downside beneath the recent 52-week low buffer - a decisive break below that level would signal either faster credit deterioration or a market re-pricing we don’t want to hold through. Target $23.00 reflects a re-rating back toward prior highs and partial recovery of book value.

If you intend to hold beyond the mid-term window, convert this into a position trade and reassess at 180 trading days (long term) if dividends remain covered and realized gains accumulate. The mid-term horizon is our primary recommendation because it balances income capture with the potential for a technical and valuation re-rate as headlines calm.

Risks and counterarguments

There are credible reasons the market has discounted Ares, and investors should weigh them carefully:

  • Credit deterioration and non-accruals: If the economy softens and non-accrual loan balances rise meaningfully, earnings and book value can be hit quickly. The market is pricing a non-trivial probability of this scenario.
  • Dividend pressure: The most recent quarter showed core earnings of roughly $0.47 versus a $0.48 dividend; a run of below-coverage quarters could force management to cut the payout, which would sharply re-rate the stock.
  • Sector headline risk: Events like redemption caps at private credit funds on 06/28/2026 create a risk-off tone. Even though ARCC is liquid and regulated, spillover sentiment can depress the stock independent of fundamentals.
  • High short interest and short-volume spikes: Short-interest data and large short-volume days suggest the stock can be volatile and subject to squeezes or quick downside moves if fresh negative information emerges.
  • Macro recession risk: A broader recession could depress earnings across the BDC space and materially increase loan losses, turning today’s yield into capital loss.

Counterargument: the market may be right to be cautious. If ARCC posts ongoing core-earnings shortfalls, raises its provisioning, or starts cutting the dividend, the valuation downshift will be justified. That path is the largest single bear case and would force a reassessment of the recommendation.

What would change my mind

I would downgrade or close the trade if any of the following occur:

  • Core earnings remain below the dividend for two consecutive quarters without offsetting realized gains or capital actions.
  • Non-accruals jump materially and are accompanied by a meaningful markdown to NAV.
  • Management explicitly changes dividend policy to a lower base or switches to irregular payouts.
  • Macro data indicate a deepening recession that meaningfully raises default expectations across the middle-market borrower base.

Conclusion

ARCC offers an asymmetric risk-reward at current levels: high running yield, a sub-1.0 P/B multiple, and technical indicators that do not signal an imminent breakdown. Short-term headline noise around private credit liquidity has likely created a buying opportunity for disciplined income investors comfortable with BDC risk. I am upgrading ARCC to Buy and recommend initiating a long at $18.50 with a $17.25 stop and a $23.00 target over a mid-term horizon (45 trading days). The trade can be held longer if credit metrics and dividend coverage normalize.

Monitor quarterly coverage, non-accrual trends, and any management commentary on buybacks or capital actions. If those read positively, the market has room to re-rate Ares closer to book and previous cycle highs.

Trade idea timestamp: 07/07/2026 15:01 EDT - execute with position sizing that respects the stop and overall portfolio income-risk allocation.

Risks

  • Rising non-accruals and loan losses could force NAV markdowns and dividend cuts.
  • Ongoing headline risk in private credit could sustain the discount regardless of ARCC's liquidity profile.
  • High short interest and episodic short-volume spikes increase volatility and downside risk.
  • Macro recession would hurt middle-market borrowers and materially pressure earnings and book value.

More from Trade Ideas

Buy OVID: Phase 1 Safety Win for OV329 and a Clear Path Into TSC and Infantile Spasms Jul 7, 2026 Oracle: A Rare Buy Zone As AI Demand Meets Execution Risk Jul 7, 2026 Berkshire Hathaway Upgrade - Take the Long Side as $540 Comes Back Into Focus Jul 7, 2026 NIO Delivery Surge Creates a Clear Margin Path — Tactical Long Opportunity Jul 7, 2026 Buy the Dip: Newmont’s Conviction Swing Trade After June's Pullback Jul 7, 2026